07th week of 2010 patent applcation highlights part 43 |
Patent application number | Title | Published |
20100041566 | ARRAYS AND METHODS FOR GUIDED CELL PATTERNING - Guided cell patterning arrays for single cell patterning, methods for making the arrays, and methods for using the arrays. | 2010-02-18 |
20100041567 | Antibody-Based Protein Microarray to Detect Long-Term Stress In Animal Tissues - A method for determining ‘stress profiles’ of wildlife by measuring the expression of a plurality of stress-activated proteins is herein described. | 2010-02-18 |
20100041568 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS - A tri-podal compound according to formula (I) wherein, each Z is the same and is a substituted or unsubstituted N-heteroaromatic single-, multiple-, or fused-ring; and each A is the same, and can represent a direct bond between the cyclohexane ring and Z, or a carboxamide group (—C(O)—N(H)—). Use of the compounds in combinatorial libraries, methods of making the tripodal compounds, sensor devices for detecting carbohydrate targets, and methods of using the tripodal compounds to detect carbohydrate targets in a sample are also disclosed. | 2010-02-18 |
20100041569 | METHODS OF USING AN ARRAY OF POOLED PROBES IN GENETIC ANALYSIS - The invention provides arrays of polynucleotide probes having at least one pooled position. A typical array comprises a support having at least three discrete regions. A first region bears a pool of polynucleotide probes comprising first and second probes. A second region bears the first probe without the second probe and a third region bears the second probe without the first probe. A target nucleic acid having segments complementary to both the first and second probes shows stronger normalized binding to the first region than to the aggregate of binding to the second and third regions due to cooperative binding of pooled probes in the first region. The invention provide methods of using such arrays for e.g., linkage analysis, sequence analysis, and expression monitoring. | 2010-02-18 |
20100041570 | APPARATUS FOR IMPLEMENTING NON-DESTRUCTIVE QUALITY CONTROL OF SUBSTRATES AND PRINTED BIOLOGICAL MICROARRAYS - A method and apparatus are provided for implementing non-destructive quality control of substrates and printed biological microarrays. A method and apparatus are provided for implementing quality control of gel-based microarrays prepared by dispensing a gel-forming composition on a solid substrate. The method utilizes the difference between the wettability properties of a supporting substrate and a gel, where the gel is hydrophilic. Condensation of vapor of a chemically inert water-soluble liquid, such as water or glycerol, on the surface of a substrate under inspection creates a layer of tiny droplets that affect both transmission and scattering of light on the surface. A pattern of condensation, characterized by spatial distribution, average size of the droplets and spacing between the droplets, reflects variation in wetting properties of the substrate. The pattern of condensation circumscribes printed microarray features to be non-destructively imaged and analyzed. | 2010-02-18 |
20100041571 | Multiplexed Lateral Flow Assay Arrays - A diagnostic test device comprising at least one membrane disposed in any of one, two, and three dimensions; at least one test sample fluid input port that receives and transfers at least one test sample fluid and onto the at least one membrane; at least one contiguous fluid flow manifold within the at least one membrane to multiplex or distribute the at least one test sample fluid; at least one contiguous fluid flow channel that operatively connects the at least one membrane to the at least one contiguous fluid flow manifold; at least one analyte assay test zone disposed within the at least one contiguous fluid flow channel; and at least one chemical capturing reagent disposed within the at least one analyte assay test zone, wherein multiple analyte assay test results are simultaneously obtained and in parallel in the diagnostic test device. | 2010-02-18 |
20100041572 | Lube Base Oil, Process for Production Thereof, and Lubricating Oil Composition - The present invention provides a lubricating base oil comprising saturated components of 90% by mass or greater, wherein the proportion of cyclic saturated components among the saturated components is not greater than 40% by mass, and by having a viscosity index of 110 or higher and an iodine value of not greater than 2.5. The lubricating base oil of the invention exhibits excellent viscosity-temperature characteristics and heat and oxidation stability while also allowing additives to exhibit a higher level of function when additives are included. The lubricating base oil of the invention is suitable for use in various lubricating oil fields, and is especially useful for reducing energy loss and achieving energy savings in devices in which the lubricating base oil is applied. | 2010-02-18 |
20100041573 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT - The present invention relates to a product of reaction between a primary and/or secondary amine and one or more active ingredients. By the present invention, there is provided a release of the active component over a longer period of time than by the use of the active itself. | 2010-02-18 |
20100041574 | PRODUCT FOR TREATING HARD SURFACES - The invention relates to the use of a product for treating hard surfaces. The product comprises compounds of general formula I or II and polymers that are obtainable by reacting the compounds with polymeric substrates, the substrates having functional groups that are selected from hydroxy groups, primary and secondary amino groups. The treated surface is protected from soiling and/or soil release from the surface is facilitated. | 2010-02-18 |
20100041575 | Detergents - Phosphate-free dishwasher detergents which contain a builder, bleaching agents, a nonionic surfactant, and also a) a copolymer comprising i) sulfonic acid group-containing monomers, ii) further ionic and/or nonionic monomers, b) methyl glycine diacetic acid. The detergents according to the invention have good cleaning and rinsing results which are comparable to those of phosphate-containing dishwasher detergents or even outdo them. | 2010-02-18 |
20100041576 | Detergent Composition - The present invention relates to an aqueous detergent composition comprising the following elements in the indicated amounts expressed as percentage by weight: a) 0.1-15% of at least one alkyl ether carboxylate of formula (I): R—O—(CH | 2010-02-18 |
20100041577 | Ultra Concentrated Liquid Laundry Detergent - This disclosure relates to ultra concentrated liquid laundry detergent (e.g., 3×+ ultra concentrated liquid laundry detergent). For example, this disclosure relates to ultra concentrated liquid laundry detergent having superior water dispersibility at low temperatures (e.g., from about 14° C. to about 19° C.). | 2010-02-18 |
20100041578 | DETERGENT COMPOSITION - A detergent composition containing:
| 2010-02-18 |
20100041579 | PARTICULATE BLEACHING COMPOSITION COMPRISING ENZYMES - Particulate bleach additive composition containing enzymes, which can be used to bleach fabrics in conjunction with a conventional granular or liquid laundry detergent. | 2010-02-18 |
20100041580 | CLEANING COMPOSITIONS FOR REMOVING ORGANIC DEPOSITS IN HARD TO REACH SURFACES - A cleaning composition for removing organic deposits from hard to reach surfaces. In its basic embodiment, the cleaning composition comprises: a) a water miscible solvent; b) an inorganic salt; and c) water. The amount of the inorganic salt is at least 20% of the total composition by weight, with at least some of the salt existing in crystalline form at 20° C. | 2010-02-18 |
20100041581 | Aqueous cleaning composition - A water soluble, non-emulsified cleaning composition for removing contaminants, especially paint and overspray, from a surface comprises from about 1 to about 90 weight percent of an aliphatic glycol diether and from about 1 to about 90 weight percent of an aliphatic glycol monoether. Water can be added to form a working solution from about 0.001 to about 90 weight percent of the entire composition. The resulting aqueous cleaning composition exhibits a pH between about 6.0 and 8.0 and a vapor pressure of less than about 0.8 millimeters of mercury at 20° C. | 2010-02-18 |
20100041582 | CLEANING COMPOSITIONS FOR REMOVING ORGANIC DEPOSITS IN HARD TO REACH SURFACES - A cleaning composition for removing organic deposits from hard to reach surfaces. In its basic embodiment, the cleaning composition comprises: a) a water miscible solvent; b) an inorganic salt; and c) water. The amount of the inorganic salt is at least 20% of the total composition by weight, with at least some of the salt existing in crystalline form at 20° C. | 2010-02-18 |
20100041583 | BENEFIT COMPOSITIONS COMPRISING POLYGLYCEROL ESTERS - The instant disclosure relates to compositions comprising selected polyglycerol esters and a treatment and/or care agent. The disclosed compositions may be useful in fabric care compositions, for example, detergents, fabric softening compositions and the like. Methods of making and using compositions comprising polyglycerol esters and a treatment and/or care agent are also disclosed. | 2010-02-18 |
20100041584 | GEM DIFLUORINATED C-GLYCOPEPTIDES, THEIR PREPARATION AND THEIR USE FOR THE PRESERVATION OF BIOLOGICAL MATERIALS AND/OR IN CRYOSUGERY - The invention concerns a gem-difluorinated C-glycopeptide compound of formula (I) in which N is an integer between 1 and 5, R | 2010-02-18 |
20100041585 | USE OF ORITAVANCIN FOR PREVENTION AND TREATMENT OF ANTHRAX - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against | 2010-02-18 |
20100041586 | METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS - Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier. | 2010-02-18 |
20100041587 | COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION - The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter. | 2010-02-18 |
20100041588 | DERIVATIVES OF APF AND METHODS OF USE - Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline. | 2010-02-18 |
20100041589 | METHODS FOR PREPARING PURIFIED LIPOPEPTIDES - The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions. | 2010-02-18 |
20100041590 | Compounds - The present invention relates to substituted 3-Aminopyrazole compounds of formula (I) | 2010-02-18 |
20100041591 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2010-02-18 |
20100041592 | Use of Amphiphilic Biocompatible Polymers for Solubilization of Hydrophobic Drugs - The present invention provides polymer aggregates as delivery vehicles for therapeutics and diagnostics. The present invention additionally provides methods of synthesis and uses for such aggregates. | 2010-02-18 |
20100041593 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN FOR TREATMENT OF ULLRICH CONGENITAL MUSCULAR DYSTROPHY - The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy. | 2010-02-18 |
20100041594 | Use of Aplidine for the Treatment of Pancreatic Cancer - Aplidine is active against cancer of the pancreas, including metastatic pancreatic cancer. | 2010-02-18 |
20100041595 | Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 3c (BMP-3c), nucleotide molecules encoding the protein and host cells expressing the protein. The present invention relates also to the use of said BMP-3c for treating disorders related to bone and cartilage formation. Osteogenic devices and pharmaceutical compositions containing the protein are also disclosed. | 2010-02-18 |
20100041596 | Amelioration of Inflammatory Arthritis By Targeting the Pre-ligand Assembly Domain (Plad) of Tumor Necrosis Factor Receptors - The present invention provides a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD) of a TNF receptor-like receptor. Also provided by this invention is a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD), wherein the PLAD is selected from the group consisting of: the PLAD of a TNF-R, the PLAD of p60, the PLAD of p80, the PLAD of Fas (CD95/APO-1), the PLAD of TRAIL receptors, the PLAD of LTyR, the PLAD of CD40, the PLAD of CD30, the PLAD of CD27, the PLAD of HVEM, the PLAD of OX40 and the PLAD of DR4. TNF-R, p60, p80, Fas, TRAIL receptor, LTyR, CD40, CD30, CD27, HVEM, OX40, DR4, TROY, EDAR, XEDAR, DCR3, AITR, 4-1BB, DR3, RANK, TACI, BCMA, DR6, DPG, DR5, DCR1 AND DCR2 are all members of the TNF receptor superfamily or the TNF-like receptor family. The invention also provides the PLAD for other members of the TNF receptor superfamily. The polypeptides of the present invention can be utilized to inhibit oligomerization of members of the TNF receptor superfamily. These polypeptides can also be utilized to inhibit ligand binding to members of the TNF receptor superfamily. The present invention also provides a composition comprising an inhibitor of TNF receptor oligomerization. Further provided by this invention are members of the TNF receptor superfamily that are lacking a PLAD. | 2010-02-18 |
20100041597 | PEPTIDES TARGETED TO PROTEIN KINASE C ISOFORMS AND USES THEREOF - Peptides having a sequence of general formula (I), or the retro form thereof, and having an affinity for one or more mammalian protein kinase C-alpha isoforms are provided: X—[(HY—HB) | 2010-02-18 |
20100041598 | Use of Prolactin in the Prophylactic Treatment of Cancer - The present invention relates to compositions and methods for treating cancer. In particular, the invention describes prolactin containing compositions for the prophylactic treatment of breast cancer. | 2010-02-18 |
20100041599 | Compositions and methods for bone formation, bone remodeling and toxin protection - The present invention identifies compounds that disrupt the interaction between anthrax proteins and LRP5/6 receptors, resulting in a reduction in anthrax toxicity. The compounds act to disrupt the intracellular transport of toxin complexes into a target cell. The present invention also provides methods for testing the effect of compounds on Wnt activity, through the use of in vitro experiments involving cells that have in at least one gene mutation involved in the Wnt pathway. | 2010-02-18 |
20100041600 | INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY ILL SUBJECTS - The invention provides methods, nucleic acids, compositions and kits for predicting a subject's outcome with an inflammatory condition and a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises determining a interferon gamma (IFNG) gene polymorphism genotype(s) of a subject for one or more polymorphisms in the IFNG gene or associated sequence, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response polymorphism to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with activated protein C or protein C like compound and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype. | 2010-02-18 |
20100041601 | Use of VEGF and homologues to treat neuron disorders - The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGF | 2010-02-18 |
20100041602 | Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules - The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation. | 2010-02-18 |
20100041603 | Method of Promoting Wound Healing - The present disclosure relates to methods of administering relaxin to promote wound healing and reduce scar formation. The disclosure further contemplates the use of relaxin in reconstructive and plastic surgery. | 2010-02-18 |
20100041604 | NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUS - The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections. | 2010-02-18 |
20100041605 | Use of VEGF-C or VEGF-D in Reconstructive Surgery - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 2010-02-18 |
20100041606 | Methods of Use of Eggshell Polypeptides - Identified herein is an active component of chicken eggshells, which is shown ex-vivo studies to have a stimulating effect on bone building cells (osteoblasts). The substance is a polypeptide mixture extracted from eggshells. It has been discovered herein that a composition comprising eggshell polypeptides stimulates osteoblasts, and has osteoinductive/osteogenic properties, hematopoietic properties, and cartilage formation or differentiation properties. The eggshell polypeptide extracts can be locally or systemically administered. | 2010-02-18 |
20100041607 | UNCTUOUS COMPOSITIONS - The present invention relates to unctuous composition containing at least one solid active ingredient, at least one hydrophobic protective colloid and at least one edible oil. The active ingredient is preferably a carotenoid. The preferred protective colloids are prolamines. The invention compositions are simple to produce, have good bioavailability and dyestuff yield, and are used an addition to animal feed agents, foods, and dietary supplements and pharmaceutical and cosmetic agents. | 2010-02-18 |
20100041608 | METHOD FOR STIMULATING WOUND HEALING - The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43 having an amino acid sequence set forth in SEQ ID NO: 1 or functional equivalents thereof. The composition used in the method of the present invention can be efficiently utilized for the wound healing, since p43, an effective ingredient of the composition, has an excellent effect on the wound healing by its action including the induction of macrophage/monocyte and endothelial cell re-epithelization, proliferation of fibroblasts or angiogenesis. | 2010-02-18 |
20100041609 | INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT - Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity. | 2010-02-18 |
20100041610 | INSECTICIDAL TOXIN COMPLEX FUSION PROTIENS - The subject invention relates to insecticidal toxin complex (“TC”) fusion proteins and to polynucleotides that encode these fusion proteins. In some embodiments, the invention provides a fusion protein comprising a Class A protein, a Class B protein, and a Class C TC protein fused together to form a single protein. In some other embodiments, the invention provides a fusion protein comprising a Class B and a Class C TC proteins fused together. In the latter embodiments, the BC or CB fusion protein can be used to enhance or potentiate the anti-insect activity of a “Toxin A” or Class A protein. The subject invention also includes plants, cells (bacterial and plant cells for example), and seeds that comprise the polynucleotides. The subject invention also includes methods of controlling pests (preferably insects and other plant pests) with fusion proteins of the subject invention. | 2010-02-18 |
20100041611 | Rapid Isolation of Osteoinductive Protein Mixtures From Mammalian Bone Tissue - A method for purifying bone-derived osteoinductive proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recover process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and approximately 100 kilodaltons. Processes of the present invention may be used to recover osteoinductive proteins from bone demineralization waste streams. | 2010-02-18 |
20100041612 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof - GLP-1 fragments and derivatives thereof are able to interact with and activate the GLP-1 receptor GLP-1 fragments and derivatives thereof are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies that are known to benefit from activation of the glucagon-like peptide-1 receptor. | 2010-02-18 |
20100041613 | NOVEL ANTIBIOTIC COMPOSITIONS - This invention is directed to antibiotic compositions comprising a targeting moiety covalently linked to an antibiotic moiety. This invention is also directed to pharmaceutical compositions comprising the antibiotic compositions of the invention and methods of making and using the antibiotic compositions of the invention. | 2010-02-18 |
20100041614 | METASTASIS-SPECIFIC PEPTIDES AND THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes. | 2010-02-18 |
20100041615 | PROTEIN-BINDING METHOTREXATE DERIVATIVES, AND MEDICAMENTS CONTAINING THE SAME - The invention relates to methotrexate derivatives which contain a protein-binding group and can be enzymatically cleaved in the body such that the active substance or a low-molecular active substance derivative is released. Also disclosed is a method for producing methotrexate derivatives, the use thereof, and medicaments comprising methotrexate derivative. | 2010-02-18 |
20100041616 | Formulations for Nonsurgical Exogenous Crosslink Therapy - Improved methods and compositions for the treatment of native tissues with crosslinkers are provided. The methods and compositions will find particular use in increasing resistance to tearing, fissuring, rupturing, and/or delamination. | 2010-02-18 |
20100041617 | Modulating mxa expression - The invention provides compositions and methods for inhibiting cell motility, metastatic cancer and viral infections in a mammal that involve increasing the activity or expression of MxA. | 2010-02-18 |
20100041618 | 6-11 Bridged Oxime Erythromycin Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2010-02-18 |
20100041619 | Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders - The present invention is directed towards lasonolide derivatives, methods of inducing premature chromosome condensation using lasonolide derivatives, and methods of treating disorders, such as cancer, in a subject, the method comprising administering to the subject a lasonolide derivative. | 2010-02-18 |
20100041620 | METHODS FOR IMPROVING FRONTAL BRAIN BIOENERGETIC METABOLISM - The invention provides methods and compositions for augmenting bioenergetic metabolism in the frontal brain involving administration of a cytidine-containing or uridine-containing compound to a human. | 2010-02-18 |
20100041621 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE PERFORMANCE - The invention provides methods and compositions for improving cognitive performance involving administration of a cytidine-containing or uridine-containing compound to a neuropsychologically healthy human. | 2010-02-18 |
20100041622 | Compositions containing aminoalkanes and aminoalkane derivatives - Provided are palatable liquid compositions that contain 2-aminoalkanes that have vasoconstrictor activity, and other additives, including taste-modifying agents. Also provided are methods for making and using the compositions to provide stimulant activity for increasing energy, alertness, endurance, and/or any other consequent physical manifestation of the vasoconstrictor activity. | 2010-02-18 |
20100041623 | Aqueous liquid preparation comprising gatifloxacin - Disclosed is an aqueous liquid preparation comprising (A) gatifloxacin, a pharmacologically acceptable salt thereof or a hydrate gatifloxacin or the salt, (B) hyaluronic acid or a pharmacologically acceptable salt thereof, and (C) a polyhydric alcohol. The aqueous liquid preparation is an ophthalmic aqueous liquid preparation excellent in the retention of gatifloxacin in a tear fluid and the penetration of gatifloxacin into an aqueous humor and a conjunctiva. | 2010-02-18 |
20100041624 | Buprenorphine formulations for intranasal delivery - Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C | 2010-02-18 |
20100041625 | PHARMACEUTICAL COMPOSITION COMPRISING CYCLODEXTRIN PACLITAXEL INCLUSION AND PREPARATION METHOD THEREOF - A pharmaceutical composition comprising cyclodextrin/paclitaxel inclusion, which consists of paclitaxel, cyclodextrin and a pharmaceutically acceptable excipient, wherein the mass ratio of the paclitaxel to cyclodextrin is 1:10-150, the said cyclodextrin is hydroxylpropyl-sulfobutyl-7-β-cyclodextrin, or sulfobutylether-7-β-cyclodextrin, or their mixture; the stability constant of the cyclodextrin/paclitaxel inclusion is Ka=5396M−1−1412M−1. The preparation method of the pharmaceutical composition is as follow: (a) A solution of cyclodextrin is added dropwise to a solution of paclitaxel in ethanol. (b) The resulting mixture is filtered through microporous membrane of 0.2-0.4 μm after being dissolved. (c) Ethanol is removed under reduced pressure to give a liquid inclusion which has the ethanol level of less than 2%, or alternatively water is also removed under reduced pressure, the resulting product is dried giving a solid inclusion. | 2010-02-18 |
20100041626 | GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS - Compositions and methods are provided related to | 2010-02-18 |
20100041627 | COMPOSITIONS COMPRISING POLYMERIC EMULSIFIERS AND METHODS OF USING SAME - Provided are compositions comprising a polymeric emulsifier, a hydrophobic agent, a wetting agent having at least one sulfonate group and at least one base-neutralizable carboxylic acid group, and a hydrophilic particulate material. Also provided are methods of mitigating diaper dermatitis using the composition, and methods of promoting the benefits associated with the compositions. | 2010-02-18 |
20100041628 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY - Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKKβ and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKKβ. In the formula, R | 2010-02-18 |
20100041629 | Nanoemulsions and Processes for their Preparation, And Their Use as Formulations of Plant Protection Agents and/or Pesticides and/or Cosmetic Preparations - Nanoemulsions and processes for their preparation, and their use as formulations of plant protection products and/or pesticides and/or cosmetic preparations. | 2010-02-18 |
20100041630 | Methods for Treating or Preventing Inflammation Using a Glycerophosphate Salt - Glycerophosphate salts have been found to mitigate the syndromes or conditions of discomfort associated with inflammation. Therefore, methods are provided for treating or preventing an inflammatory condition using a glycerophosphate salt. In particular, methods are provided for treating or preventing an inflammatory condition using calcium glycerophosphate (CGP). | 2010-02-18 |
20100041631 | METHODS AND AGENTS FOR TREATING TUBERCULOSIS - The present invention relates to the treatment of tuberculosis (mycobacterial infections) by the use of KshAB complex inhibitors, or a KstD molecule, or a HsaAB complex, or a HsaC molecule, or a HsaD molecule. The application also includes a method for identifying an inhibitor or modulator of the previously mentioned molecules and complexes. | 2010-02-18 |
20100041632 | USES OF THE CARBOXY-AMIDO-TRIAZOLE COMPOUNDS AND SALTS THEREOF - The present invention relates to new medical use of CAI and its analogs/derivates together with the pharmaceutically acceptable salts thereof. Particularly, the use of CAI and its analogs/derivates, together with pharmaceutically acceptable salts thereof as TNF-α and IL-1β inhibitor and the use of these compounds in preparation of formulations for treatment of TNF-α and/or IL-1β mediated diseases other than malignant tumor especially of painful diseases and/or inflammatory diseases are provided herein. | 2010-02-18 |
20100041633 | NITRIC OXIDE RELEASING STEROIDS - The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof wherein R is a corticosteroid residue selected from: The compounds are useful in the treatment of respiratory diseases. | 2010-02-18 |
20100041634 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy - The invention relates to compounds of the general formula (I): | 2010-02-18 |
20100041635 | OXINDOLE COMPOUNDS - The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation. | 2010-02-18 |
20100041636 | NOVEL KINASE INHIBITORS - The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. | 2010-02-18 |
20100041637 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11 -hydroxysteroid dehydrogenase 1 - This invention relates to novel compounds of the Formula (I), (I*), (I**), I, Ia, Ib, Ic, Id, Ie, If, Ig, Il | 2010-02-18 |
20100041638 | Chemical Compounds 293 - The present invention provides a compound of a formula (I): | 2010-02-18 |
20100041639 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION - This invention relates to novel cyclic malonamides having the formula (I): | 2010-02-18 |
20100041640 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - β-Crystalline form of ivabradine of formula (I): | 2010-02-18 |
20100041641 | USES OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 2010-02-18 |
20100041642 | UREA INHIBITORS OF MAP KINASES - Urea containing compounds that inhibit MAP kinases, pharmaceutical compositions including such compounds and methods for using these compounds to treat inflammatory diseases and cancer are described herein. | 2010-02-18 |
20100041643 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF - [Solving means] A thienotriazolodiazepine compound of the following formula (I) | 2010-02-18 |
20100041644 | STABILIZED SOLID PHARMACEUTICAL COMPOSITION OF CANDESARTAN CILEXETIL - The present invention relates to a solid pharmaceutical composition containing candesartan cilexetil as active ingredient and a stabilizing agent selected from the group consisting of esters of saturated fatty acids and monohydroxy alcohols, esters of hydroxycarboxylic acids and monohydroxy alcohols, ethers of C | 2010-02-18 |
20100041645 | RHO KINASE INHIBITORS - Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma. | 2010-02-18 |
20100041646 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants - The present application relates to novel 1,4-phenylene-bis-oxazolidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders. | 2010-02-18 |
20100041647 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses - This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment. | 2010-02-18 |
20100041648 | METHODS FOR TREATING RETROVIRAL INFECTIONS - The present invention provides compositions for treating an HIV infection comprising administering a compound according to formula I where Ar, R | 2010-02-18 |
20100041649 | INHIBITORS OF PAPILLOMA VIRUS - A compound of formula (I) or its enantiomers or diastereoisomers thereof: | 2010-02-18 |
20100041650 | PURINE COMPOUNDS AS CANNABINOID RECEPTOR BLOCKERS - The present invention relates to purine-based cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, inflammatory disorders, hepatic disorders, and a combination thereof. | 2010-02-18 |
20100041651 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives of general formula (I): | 2010-02-18 |
20100041652 | TYROSINE KINASE INHIBITORS - The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds. | 2010-02-18 |
20100041653 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS - The present disclosure provides compounds having the general structure A or pharmaceutically acceptable salts thereof: | 2010-02-18 |
20100041654 | Pyrimidine Derivatives And Their Use As CB2 Modulators - This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor. | 2010-02-18 |
20100041655 | TRIAZOLE DERIVATIVE - An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P | 2010-02-18 |
20100041656 | Novel amide derivatives and medicinal use thereof - The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action | 2010-02-18 |
20100041657 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES - The present invention relates to compounds of formula I, in which at least one of R5, R6 and R7 is SR12, S(O)R12 or S(O)2R12 group where R12 is a C1-6haloalkyl group, that act, as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith. | 2010-02-18 |
20100041658 | Hydroxyphenyl Derivatives and Biological Applications Thereof - The invention relates to hydroxyphenyl derivatives of formula (I); and uses thereof as anti-bacterial and/or anti-parasitic agents. | 2010-02-18 |
20100041659 | Compositions for the control of plant pests - The present invention provides a composition comprising synergistic amounts of a compound of the formula (I) | 2010-02-18 |
20100041660 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES - The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): | 2010-02-18 |
20100041661 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD - The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 2010-02-18 |
20100041662 | Heterocyclic compounds as antiinflammatory agents - A compound of Formula Ia or Ib in free or salt or solvate form, where R | 2010-02-18 |
20100041663 | Organic Compounds as Smo Inhibitors - The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway. | 2010-02-18 |
20100041664 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS - The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): | 2010-02-18 |
20100041665 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS - The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder. | 2010-02-18 |